You are subscribed to Oncology (Cancer) / Hematologic Malignancies. This information has recently been updated, and is now available.

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to Esdek@podam.pl using Granicus Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA